ClinicalTrials.gg
RecruitingNCT06639347Updated Nov 18, 2024

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

A Phase 1/2 interventional study of SHR-A2102 and Adebrelimab injection in Advanced Urothelial Carcinoma, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with Antitumor Therapy in Advanced Urothelial Carcinoma. To explore the reasonable dosage of SHR-A2102 for Advanced Urothelial Carcinoma.

02

Conditions studied

  • Advanced Urothelial Carcinoma
03

In context

Lead sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd. is the lead sponsor of 61 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Competent to comprehend, sign, and date an form.
  2. Male or female subjects must be age 18 or older.
  3. (ECOG) performance status of 0 or 1.
  4. Subjects must have documented, unresectable locally advanced or
  5. Histologically confirmed locally advanced or urothelial cancer.Phase Ib, subjects must have failed, be intolerant or refused the standard treatment; Phase II, subjects must not have received systemic antitumor therapy for locally advanced unresectable or metastatic urothelial carcinoma.
  6. An sample or a fresh tissue sample should be provided.
  7. Subjects must have according to (version 1.1).

Exclusion criteria

Exclusion Criteria:

  1. Subjects with not adequately treated, or uncontrollable , or active .
  2. Subjects who have previously received TOPO1-based ADCs.
  3. Subjects who have received anti-cancer treatment within 4 weeks prior the first dose of study treatment.
  4. Subjects who have received radiotherapy within 14 days , or chest radiotherapy > 30Gy within 6 months prior to the first dose of study drug.
  5. Subjects with ongoing toxicity associated with prior treatment that has not resolved to ≤ Grade 1.
  6. Subjects who have received systemic treatment within 14 days prior the first dose of study treatment.
  7. Subjects who have known or suspected interstitial pneumonitis.
  8. Phase Ib: Subjects who have had≥ Grade 3 irAEs during the previous treatment with ICIs.
  9. Subjects who have any active, known or suspected diseases.
  10. Subjects who have moderate or severe ascites with clinical symptoms, or uncontrolled or moderate or above pleural effusion, or pericardial effusion.
  11. Subjects who have uncontrolled cardiac diseases or cardiac clinical symptoms.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    SHR-A2102 + Adebrelimab injection+SHR-8068 injection

    Drug: SHR-A2102 · Drug: Adebrelimab injection · Drug: SHR-8068 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Phase I: RP2D of SHR-A2102 combined with Adebrelimab and SHR-8068 in patients with advanced urothelial cancer

    Time frame: Up to approximately 5 years

  2. Phase I: Incidence and severity of adverse events

    Time frame: Up to approximately 5 years

  3. Phase II: ORR by investigator assessment

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Phase I: ORR by investigator assessment

    Time frame: Up to approximately 5 years

  2. Phase I: DCR by investigator assessment

    Time frame: Up to approximately 5 years

  3. Phase I: DoR by investigator assessment

    Time frame: Up to approximately 5 years

  4. Phase I: PFS by investigator assessment

    Time frame: Up to approximately 5 years

  5. Phase I: OS by investigator assessment

    Time frame: Up to approximately 5 years

  6. Phase I: Pharmacokinetic parameter for serum concentrations of SHR-A2102 and free toxin

    Time frame: Up to approximately 5 years

  7. Phase I: Anti-SHR-A2102 antibody (ADA) and anti-SHR-A2102 neutralizing antibody (NAb)

    Time frame: Up to approximately 5 years

  8. Phase II: DCR by investigator assessment

    Time frame: Up to approximately 5 years

  9. Phase II: DoR by investigator assessment

    Time frame: Up to approximately 5 years

  10. Phase II: PFS by investigator assessment

    Time frame: Up to approximately 5 years

  11. Phase II: OS by investigator assessment

    Time frame: Up to approximately 5 years

  12. Phase II: Incidence and severity of adverse events

    Time frame: up to 5 years

  13. Phase II: Pharmacokinetic parameter for serum concentrations of SHR-A2102 and free toxin

    Time frame: Up to approximately 5 years

  14. Phase II: Anti-SHR-A2102 antibody (ADA) and anti-SHR-A2102 neutralizing antibody (NAb)

    Time frame: Up to approximately 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for May 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 15, 2024
StartActual
Nov 4, 2024
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06639347
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Nov 4, 2024
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 18, 2024

Study contacts

Chun Yang
Contact
chun.yang.cy35@hengrui.com
+86 15001953916

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Notiretatug rezetecan

Start the discussion